Ann Chauffe
Rheumatology · Gainesville, FLNPI 1306039201
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 71.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $24,996 and has fallen 63.9% since, to $9,024 in 2023.
Across 175 payments — averaging $282.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$35K
- Regeneron$7K
- UCB, Inc.$4K
- Argenx US, Inc.$2K
- Pfizer$247
- Amgen$224
- plus $1K from 17 others
Across 1 payment — averaging $177,048 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$177K
What the payments were for
- Consulting fees$21,77544%
- Speaking & faculty fees$11,56023%
- Travel & lodging$12,44025%
- Food & beverage$3,5657%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 43 | $35,166 |
| Regeneron | 16 | $7,234 |
| UCB, Inc. | 15 | $3,594 |
| Argenx US, Inc. | 3 | $1,571 |
| Pfizer | 14 | $247 |
| Amgen(2 entities) | 12 | $224 |
| Mallinckrodt Enterprises LLC | 12 | $203 |
| Bristol Myers Squibb | 11 | $190 |
| AstraZeneca(2 entities) | 4 | $175 |
| Radius Health, Inc. | 6 | $128 |
| Novartis | 6 | $125 |
| Lilly USA, LLC | 6 | $97 |
| Genentech USA, Inc. | 3 | $77 |
| AbbVie | 5 | $72 |
| GSK | 4 | $60 |
| Medexus Pharma, Inc. | 4 | $52 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| EMD Serono, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Antares Pharma, Inc. | 2 | $26 |
| Shire North American Group Inc | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,403 in reported general payments places this provider in the 85th percentile of 453 rheumatology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 18 | $496 |
| MethotrexateMethotrexate Sodium | 24 | $346 |
| Celecoxib | 16 | $141 |
| Prednisone | 18 | $121 |
| Allopurinol | 12 | $79 |
| Omeprazole | 13 | $50 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Gainesville
- Dina HammadGainesville$62K
- Newton EdwardsGainesville$59K
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
- Julio Gonzalez-PaoliTampa$1.4M
- Ernesto RodriguezZephyrhills$958K
- Vinicius Costa Diniz DominguesDaytona Beach$921K
- Jonathan GreerBoynton Beach$757K
- Jigar ShahMargate$750K
- Rachel TateHollywood$729K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.